



www.genfit.com

GENFIT: RESERVED CAPITAL INCREASE

- **YA Global Master SPV Ltd, managed by the investment company Yorkville Advisors LLC, invests a further €600 K.**

Lille (France), Cambridge (Massachusetts, United States), May 2nd, 2012 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces the achievement of a private placement of €600,000.62 (issue premium included), reserved to one of its historical shareholders - YA Global Master SPV Ltd – a holding managed by the investment company Yorkville Advisors LLC, at the price of €1.78 per share.

This price represents a discount of 18.8% compared to the volume-weighted average share price during the five trading days immediately preceding the date on which the issue price was fixed.

The operation, performed following the decisions of the Management Board of April 27th and May 2nd, 2012, and according to the delegations granted to the Management Board by the Twentieth and Twenty-First Resolutions of the Extraordinary General Meeting of Shareholders held on June 28, 2011, will result in the issue of 337,079 new shares immediately assimilated with existing shares. The number of shares that make up the capital will thus increased to 14,668,998.

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases...). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments, and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies including Sanofi, to address these major public health concerns and their unmet medical needs.

GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase II.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 100 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com

Contacts:

GENFIT

Jean-François Mouney – CEO & Chairman of the Management Board
Ph. +333 2016 4000

MILESTONES – Press Relations

Bruno Arabian
Ph. +33 1 7544 8740 / +336 8788 4726 – barabian@milestones.fr